Some patients reach their target dose faster, while others need additional time at intermediate levelsyour individual pharmacodynamics matter more than the calendar
Focusing on lean protein, whole grains, healthy fats, and plenty of vegetables can help support steady progress
Now, Lilly recently reported topline results from the ATTAIN-1 phase-3 trial evaluating orforglipron, a once-daily oral glucagon-like-peptide-1 (GLP-1) receptor agonist for adults with obesity or overweight without diabetes
Unlike general bloating, which can strike at any time, morning bloating often stems from overnight processes, such as slowed digestion during sleep
Rybelsus is approved only for type 2 diabetes and does not have FDA approval for weight loss
Environ Health Perspect, 103(suppl 6): 249-252